Wall Street brokerages expect that Orchard Therapeutics PLC – (NASDAQ:ORTX) will announce earnings of ($0.49) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Orchard Therapeutics’ earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.56). The business is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Orchard Therapeutics will report full year earnings of ($2.32) per share for the current financial year, with EPS estimates ranging from ($2.83) to ($1.81). For the next year, analysts forecast that the business will report earnings of ($2.26) per share, with EPS estimates ranging from ($2.68) to ($1.84). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Orchard Therapeutics.

A number of analysts recently commented on the stock. Zacks Investment Research cut shares of Orchard Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 2nd. Wedbush restated an “outperform” rating and set a $25.00 price target on shares of Orchard Therapeutics in a research note on Friday, March 22nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $23.40.

Shares of ORTX stock opened at $19.02 on Wednesday. The company has a market cap of $1.65 billion and a P/E ratio of -1.86. Orchard Therapeutics has a 12 month low of $8.65 and a 12 month high of $21.64.

Hedge funds have recently made changes to their positions in the stock. Legacy Advisors LLC purchased a new stake in shares of Orchard Therapeutics during the 1st quarter valued at approximately $53,000. Lindbrook Capital LLC purchased a new stake in shares of Orchard Therapeutics during the 1st quarter valued at approximately $53,000. Victory Capital Management Inc. purchased a new stake in shares of Orchard Therapeutics during the 4th quarter valued at approximately $106,000. PNC Financial Services Group Inc. purchased a new stake in shares of Orchard Therapeutics during the 1st quarter valued at approximately $116,000. Finally, Jabodon PT Co. purchased a new stake in shares of Orchard Therapeutics during the 1st quarter valued at approximately $550,000. Institutional investors own 56.60% of the company’s stock.

About Orchard Therapeutics

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Recommended Story: 52-Week High/Low

Get a free copy of the Zacks research report on Orchard Therapeutics (ORTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.